Singapore, March 22, 2024 — Labcorp is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 67,000 employees serve clients in over 100 countries, worked on over 84% of the new drugs approved by the FDA in 2023 and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
“APAC is a critical region to the success of Labcorp’s central laboratories. Increasing our global laboratory footprint allows us to offer shorter turnaround times, superior in-country sample management and full lab testing services for global clinical trials. The efforts of our global workforce benefit patients, clients and healthcare providers by providing them with the information they need to make key decisions,” said Jon DiVincenzo, EVP and president, central laboratories services and international.
We are honored to receive this recognition, which was voted on by our biopharma colleagues. We are humbled to be recognized for our efforts in innovation, service and technology and look forward to continuing and deepening the collaborative relationships with our peers and stakeholders.”
In 2023, Labcorp expanded our Bioanalytical Service Offering in our Singapore lab. The Singapore-based bioanalytical laboratory is now a full service provider of regulated and non-regulated services supporting the development of both small and large molecular entities.
Also in 2023, Labcorp announced the opening of a new kit production facility, as well as the completed expansion of its immunology and immunotoxicology lab in China, as part of its global growth and investment strategy.
And this year, Labcorp and BioMedical Laboratories (BML) began work on a new laboratory facility in the city of Kawagoe, Saitama, to expand capacity and services for pharmaceutical and biotechnology clients. This will bolster Labcorp central laboratory services offerings in Japan and sets the stage for a continued acceleration of companion diagnostic capabilities.
The additional capacity in such strategic and important regions serves to strengthen our extensive global presence and offers in-region and international clients a complementary site in Asia-Pacific for support of their bioanalytical studies.
Working in collaboration with our diagnostics laboratories, Labcorp continues to develop, license and launch new tests that can be used to support clinical trials in areas of deep clinical interest and need, including oncology, women’s health, autoimmune and neurology.
For central laboratory customers, Labcorp introduced a new Sample Tracking Application to provide enhanced, near real-time visibility of specimens within the central lab, along with an electronic requisition system that will support greater efficiency and reduce errors in test and supply ordering.
About IMAPAC
IMAPAC is a leading event management company specializing in the biopharmaceutical industry. With over 12 years of experience, IMAPAC has successfully organized more than 50 industry events, attracting over 15,000 participants from around the world. IMAPAC’s events are renowned for their high-quality content, prestigious speakers, and networking opportunities.
